Skip to content

Mistras Group

US · MG #3552 by market cap
20.19 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Roth MKM Downgrades Mistras Group(MG.US) to Hold Rating, Cuts Target Price to $20.35
    Market Newswire · 2026/11/3
  • Rating change
    CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 Mg BID Regimen; Buy Rating and $12 Price Target Reiterated
    TipRanks · 2026/9/28
  • Company notice
    UNITAS HOLD: Form of proxy for use at the annual general meeting to be held at Flat C, 16/F., MG Tower, 133 Hoi Bun Road, Kwun Tong, Kowloon, Hong Kong on Wednesday, 30 September 2026 at 11:00 a.m. or any adjournment thereof (the "Annual General Meeting")
    HKEX · 2026/9/4
  • Rating change
    Roth MKM Maintains Mistras Group(MG.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/5/8
  • Hengrui Pharma (600276): Impressive Phase II data for SHR-1139; PASI 90 response rate reached 92.7% at week 16 in the 600 mg cohort.
    Tianfeng Securities · 2026/10/8
  • Rating change
    Zhongsheng Pharmaceutical (002317): Results from the Phase II RAY1225 study were presented at ADA, with the 18 mg dose group demonstrating superior weight‑loss efficacy.
    Zheshang Securities · 2026/6/10
  • Company notice
    Eisai: The subcutaneous injection formulation of "Rekenbi," "Rekenbi Subcutaneous Injection 250 mg Pen," has been newly launched in Japan as a treatment for early-stage Alzheimer's disease.
    JPX · 2026/11/13
  • Company notice
    Eisai: The subcutaneous formulation of the early-stage Alzheimer's disease treatment "Rekembi," the "Rekembi Subcutaneous Injection 250 mg Pen," has received approval in Japan.
    JPX · 2026/9/16
  • Rating change
    Research Report Insights | Zheshang Securities: Initiates "Buy" rating on Zhongsheng Pharmaceutical, citing superior weight-loss efficacy in the 18mg dose group
    Gelonghui Finance · 2026/6/11
  • Rating change
    EF Hutton: The MISTRAS Group (MG.US) rating was downgraded from buy to hold, and the target price was adjusted from $12.00 to $11.00.
    Zhitong Finance · 2024/5/3
  • Rating change
    Vyvgart's Strengthening MG Franchise and Pipeline Catalysts Support Buy Rating on Argenx
    TipRanks · 2026/2/26
  • China Isotope & Radiation Corporation (01763.HK) Receives Registration Certificate for 50mg Urea 13C Breath Test Kit
    AASTOCKS · 2026/10/12
  • Company notice
    Mistras Group: MISTRAS Group, Inc. - Anticipated Cash Settlement Option Symbol: MG
    OCC · 2026/11/3
  • Eli Lilly Announces Detailed Results From TRIUMPH-2; TRIUMPH-2 Participants With Obesity And Type 2 Diabetes Taking Retatrutide 12 Mg Lost An Average Of 49.6 Lbs Over 80 Weeks; Retatrutide 12 Mg Leads To 60.8 Lb Weight Loss In BMI ≥35 Group; To Submit...
    Benzinga · 2026/9/30
  • Rating change
    Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential
    TipRanks · 2026/4/21
  • Rating change
    Roth MKM Initiates Mistras Group(MG.US) With Buy Rating, Announces Target Price $22
    Market Newswire · 2026/4/30
  • Company notice
    Fuji Pharma: Marketing Approval for new specification of Golimumab Biosimilar― GOLIMUMAB BS 50mg autoinjector for S.C. injection「F」 ―
    JPX · 2026/9/16
  • Rating change
    TR | OpenAI - 4o Maintains Mistras Group(MG.US) With Hold Rating, Maintains Target Price $9.5
    Market Newswire · 2025/8/11
  • Rating change
    Texas Capital Securities Initiates Mistras Group(MG.US) With Buy Rating, Announces Target Price $16
    Market Newswire · 2025/11/21
  • China Isotope & Radiation Corporation (01763.HK): CNNC Hede Wei’s 50mg Urea 13C Breath Test Kit Receives Drug Registration Certificate
    Gelonghui Finance · 2026/10/9
  • Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To...
    Benzinga · 2026/9/29
  • Company notice
    Nippon Kayaku: A contract has been concluded regarding the succession of manufacturing and marketing approval for "Zoladex 3.6 mg Depot/LA 10.8 mg Depot."
    JPX · 2026/5/25
  • Company notice
    Zhongguancun: Announcement Regarding the Receipt by Its Subsidiary, Beijing Huasuo Duotinole Tablets (1 mg and 2 mg), of the \"Notice of Acceptance\" from the National Medical Products Administration.
    SZSI · 2026/8/6
  • Henlius Biopharma (02696.HK): The National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for the marketing authorization of HLX14, a denosumab biosimilar, in the 120 mg (1.7 ml)/vial specification.
    Gelonghui Finance · 2026/9/11
  • Shijiazhuang No.4 Pharmaceutical Group (02005.HK): Obtained drug production registration approval for Vitamin K1 Injection (1ml: 10mg)
    Gelonghui Finance · 2026/8/20

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Mistras Group discussion 0 comments

Add a comment